Jon Giles, MD
Rheumatology · Los Angeles, CANPI 1679511810
Payments from drug & device makers
Across 548 payments — averaging $498.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$60K
- Eli Lilly$42K
- AbbVie$35K
- Novartis$28K
- Amgen$25K
- Janssen Scientific Affairs, LLC$17K
- plus $67K from 13 others
Across 24 payments — averaging $1177.60 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$28K
- F. Hoffmann-la Roche AG$102
What the payments were for
- Consulting fees$131,86753%
- Speaking & faculty fees$66,55127%
- Travel & lodging$43,39317%
- Food & beverage$6,1502%
- Education$510%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 72 | $59,808 |
| Eli Lilly | 45 | $41,504 |
| AbbVie | 87 | $34,671 |
| Novartis | 84 | $27,951 |
| Amgen | 1 | $25,353 |
| Janssen Scientific Affairs, LLC | 123 | $17,237 |
| Gilead | 3 | $15,435 |
| E.r. Squibb & Sons, L.L.C. | 47 | $14,503 |
| UCB, Inc. | 15 | $10,356 |
| F. Hoffmann-la Roche AG | 3 | $9,537 |
| Merck | 9 | $5,110 |
| Roche Products Limited | 7 | $4,363 |
| Jubilant Draximage Inc. | 1 | $2,000 |
| Sanofi | 14 | $1,770 |
| Lilly USA, LLC | 9 | $1,747 |
| Genentech, Inc. | 18 | $811 |
| Genentech USA, Inc. | 7 | $726 |
| Assertio Therapeutics, Inc. | 2 | $355 |
| Regeneron Healthcare Solutions, Inc. | 1 | $128 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$273,365 in reported general payments places this provider in the 90th percentile of 808 rheumatology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Orencia ClickjectAbatacept | 12 | $83,341 |
| MethotrexateMethotrexate Sodium | 45 | $2,094 |
| Hydroxychloroquine Sulfate | 40 | $1,771 |
| Prednisone | 25 | $260 |
| Celecoxib | 15 | $164 |
| Meloxicam | 30 | $135 |
| Allopurinol | 15 | $131 |
| Cyclobenzaprine Hcl | 21 | $86 |
Paid to pharmacies, not to this prescriber.
Other rheumatology in Los Angeles
- Christina Charles-SchoemanLos Angeles$4.8M
- Elizabeth VolkmannLos Angeles$1.3M
- Maureen McMahonLos Angeles$1.1M
- Karina Marianne TorralbaLos Angeles$633K
- Suzanne KafajaLos Angeles$589K
- Haoling WengLos Angeles$562K
- Veena RanganathLos Angeles$532K
- Glenn EhresmannLos Angeles$450K
- Samy MetyasCovina$12.9M
- Christine ThaiHuntington Beach$8.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.